A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer | Journal of Translational Medicine | Full Text
Rapid Readouts: Three-Year Update From CheckMate 227, Part 1
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
CheckMate 227 Part 1: 4-Yr Update - Slideset Download - Clinical Oncology 2021 | CCO
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1 - ScienceDirect
Nivolumab + Ipilimumab vs Platinum-Doublet Chemotherapy as First-line Treatment for Advanced Non-Small Cell Lung Cancer: Initial Results From CheckMate. - ppt download
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1 | International Journal of Clinical Oncology
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1 | International Journal of Clinical Oncology
Solange Peters, Switzerland: CheckMate 227 Part 1 final analysis
ESMO | Press | immunotherapy, chemotherapy, NSCLC, Checkmate227
ASCO 2020 Lung Cancer Highlights | Value-Based Cancer Care
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer | Journal of Translational Medicine | Full Text
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
Advances with First-Line Dual Immunotherapies in Metastatic Non-Small Cell Lung Cancer – OncoPrescribe
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1 | International Journal of Clinical Oncology
Dual IO Therapy in Advanced NSCLC: Long-Term Followup From CheckMate 227
Optimizing frontline immunotherapy for advanced NSCLC - touchONCOLOGY
1L mNSCLC (PD-L1 ≥1%) Efficacy
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial - ScienceDirect
Jacob Plieth on X: "So new $BMY Checkmate 227 design should look sth like this (cf $RHBBY atezeo + chemo #WCLC2015) http://t.co/KKGULGxhEY" / X
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 | Journal of Clinical Oncology
